Eli Lilly and Company (LLY) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Total Cash From Operating Activities Chart for Eli Lilly and Company

Eli Lilly and Company (LLY) operating cash flow for FY2025 was USD 16.8B, a 90.7% change from FY2024. Eli Lilly and Company's operating cash flow grew from USD 1.0B in 1989 to USD 16.8B in 2025 (1528.2% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 20.9%, 10-year CAGR of 19.0%, 20-year CAGR of 11.5%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.06T
Implied Share Price
$1191.94
Enterprise Value
$1.03T
Revenue (TTM)
$79.67B
EBITDA
$41.68B
Profit Margin
33.53%
Trailing P/E
39.22
Forward P/E
32.89
Price/Book (MRQ)
31.89
Price/Sales (TTM)
13.34
EV/EBITDA
28.52
EV/Revenue
14.30
Dividend Yield
0.55%
Book Value
$34.92
Free Cash Flow (FY2025)
$8.97B
Free Cash Flow Yield
0.84%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.